Nelfinavir

Brand names: Viracept · Active ingredient: Nelfinavir Mesylate

In short: VIRACEPT in combination with other antiretroviral agents is indicated for the treatment of HIV-1 infection.

Forms & strengthsVIRACEPT 250 mg Tablet: Light-blue, capsule-shaped tablets with a clear film coating engraved with "VIRACEPT" on one side and "250 mg" on the other. …
LabelAgouron
Label updatedDec 12, 2025

What is Nelfinavir used for?

VIRACEPT in combination with other antiretroviral agents is indicated for the treatment of HIV-1 infection.

Nelfinavir dosage

The recommended dose is 1250 mg (five 250 mg tablets or two 625 mg tablets) twice daily or 750 mg (three 250 mg tablets) three times daily. VIRACEPT should be taken with a meal. Patients unable to swallow the 250 or 625 mg tablets may dissolve the tablets in a small amount of water .

In children 2 years of age and older, the recommended oral dose of VIRACEPT Oral Powder or 250 mg tablets is 45 to 55 mg/kg twice daily or 25 to 35 mg/kg three times daily. All doses should be taken with a meal. Doses higher than the adult maximum dose of 2500 mg per day have not been studied in children.

For children unable to swallow tablets, VIRACEPT 250 mg tablet(s) may be dissolved in a small amount of water or, VIRACEPT Oral Powder may be administered .

The healthcare provider should assess appropriate formulation and dosage for each patient. Tables 1 and 2 provide dosing guidelines for VIRACEPT tablets and powder based on age and body weight.

Body weight | Twice daily (BID)

45 – 55 mg/kg

≥2 years | Three times daily (TID)

25 – 35 mg/kg

≥2 years

Number of tablets

(250 mg) | Number of tablets

(250 mg)

Kg

10 – 12 | 2 | 1

13 – 18 | 3 | 2

19 – 20 | 4 | 2

≥21 | 4 – 5For BID dosing, the maximum dose per day is 5 tablets BID | 3For TID dosing, the maximum dose per day is 3 tablets TID

Body weight | Twice daily (BID)

45 – 55 mg/kg | Three times daily (TID)

25 – 35 mg/kg

Kg | Scoops of powder(50 mg/1 g) | TeaspoonsIf a teaspoon is used to measure VIRACEPT oral powder, 1 level teaspoon contains 200 mg of VIRACEPT (4 level scoops equals 1 level teaspoon) of powder | Scoops of powder(50 mg/1 g) | Teaspoons of powder

9.0 to <10.5 | 10 | 2½ | 6 | 1½

10.5 to <12 | 11 | 2¾ | 7 | 1¾

12 to <14 | 13 | 3¼ | 8 | 2

14 to <16 | 15 | 3¾ | 9 | 2¼

16 to <18 | Not recommendedUse VIRACEPT 250 mg tablet | Not recommended | 10 | 2½

18 to <23 | Not recommended | Not recommended | 12 | 3

≥23 | Not recommended | Not recommended | 15 | 3¾

For Patients Unable to Swallow Viracept Tablets

•Place VIRACEPT tablet(s) in small amount of water.

•Once dissolved, mix the cloudy liquid well, and consume it immediately.

•The glass should be rinsed with water and the rinse swallowed to ensure the entire dose is consumed.

Viracept Oral Powder

•Mix VIRACEPT Oral Powder with a small amount of water, milk, formula, soy formula, soy milk, or dietary supplements

•Once mixed, the entire contents must be consumed in order to obtain the full dose.

•If the mixture is not consumed immediately, it must be stored under refrigeration, but storage must not exceed 6 hours.

•Acidic food or juice (e.g., orange juice, apple juice, or apple sauce) are not recommended for mixing VIRACEPT Oral Powder because the combination may result in a bitter taste. …

How to take Nelfinavir — instructions & advice from the label

See FDA-approved patient labeling (Patient Information)

A statement to patients and healthcare providers is included on the product's bottle label: ALERT: Find out about medicines that should NOT be taken with VIRACEPT.

Instruction for Use

For optimal absorption, patients should be advised to take VIRACEPT with food.

Patients should be informed that VIRACEPT Tablets are film-coated and that this film-coating is intended to make the tablets easier to swallow.

If a dose of VIRACEPT is missed, patients should take the dose as soon as possible and then return to their normal schedule. However, if a dose is skipped, the patient should not double the next dose.

Adult or pediatric patients unable to swallow the tablets may dissolve the tablets in a small amount of water:

•Place VIRACEPT tablet(s) in small amount of water

•Once dissolved, mix the cloudy liquid well, and consume it immediately. …

Warnings & precautions

Do not take this medicine if: Coadministration of VIRACEPT is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events. These drugs and other contraindicated drugs (which may lead to reduced efficacy of nelfinavir) are listed in Table 3 [also see Drug Interactions (7), Table 6].

Drug Class | Drugs Within Class That Are Contraindicated With VIRACEPT | Clinical Comment

Alpha 1-adrenoreceptor antagonist | Alfuzosin | Potentially increased alfuzosin concentrations can result in hypotension.

Antiarrhythmics | Amiodarone, quinidine | Potential for serious and/or life-threatening cardiac arrhythmia.

Antimycobacterial Agents | Rifampin | Plasma concentrations of nelfinavir can be reduced by concomitant use of rifampin. This may lead to loss of therapeutic effect and possible development of resistance to VIRACEPT or other coadministered antiretroviral agents.

Antipsychotics | Lurasidone

Pimozide | Potential for serious and/or life-threatening reactions.

Potential for serious and/or life threatening reactions such as cardiac arrhythmias.

Ergot Derivatives | Dihydroergotamine, ergotamine, methylergonovine | Potential for serious and/or life threatening reactions such as ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.

GI Motility Agent | Cisapride | Potential for serious and/or life threatening reactions such as cardiac arrhythmias.

Herbal products | St. John's wort (Hypericum perforatum) | Plasma concentrations of nelfinavir can be reduced by concomitant use of the herbal preparation St. John's wort. This may lead to loss of therapeutic effect and possible development of resistance to VIRACEPT or other coadministered antiretroviral agents. …

Nelfinavir side effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of VIRACEPT was studied in over 5000 patients who received drug either alone or in combination with nucleoside analogues. The majority of adverse events were of mild intensity. The most frequently reported adverse event among patients receiving VIRACEPT was diarrhea, which was generally of mild to moderate intensity.

Drug-related clinical adverse experiences of moderate or severe intensity in ≥2% of patients treated with VIRACEPT coadministered with d4T and 3TC (Study 542) for up to 48 weeks, or with ZDV plus 3TC (Study 511) for up to 24 weeks are presented in Table 4. …

Drug interactions

Nelfinavir is an inhibitor of CYP3A. Coadministration of VIRACEPT and drugs primarily metabolized by CYP3A (e.g., dihydropyridine calcium channel blockers, HMG-CoA reductase inhibitors, immunosuppressants, and PDE5 inhibitors) may result in increased plasma concentrations of such drugs that could increase or prolong both its therapeutic and adverse effects .

Nelfinavir is metabolized by CYP3A and CYP2C19. Coadministration of VIRACEPT and drugs that induce CYP3A or CYP2C19, such as rifampin, may decrease nelfinavir plasma concentrations and reduce its therapeutic effect. Coadministration of VIRACEPT and drugs that inhibit CYP3A or CYP2C19 may increase nelfinavir plasma concentrations.

Table 6 provides the effect on concentrations of VIRACEPT or concomitant drug as a result of coadministration with VIRACEPT. These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious adverse events or loss of efficacy. …

About this medicine

VIRACEPT® (nelfinavir mesylate) is an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease. VIRACEPT Tablets are available for oral administration as a light-blue, capsule-shaped tablet with a clear film coating in 250 mg strength (as nelfinavir-free base) and as a white oval tablet with a clear film coating in 625 mg strength (as nelfinavir-free base). Each tablet contains the following common inactive ingredients: calcium silicate, crospovidone, magnesium stearate, hypromellose, and triacetin. In addition, the 250 mg tablet contains FD&C blue #2 powder and the 625 mg tablet contains colloidal silicon dioxide. VIRACEPT Oral Powder is available for oral administration in a 50 mg/g strength (as nelfinavir-free base) in bottles. The oral powder also contains the following inactive ingredients: microcrystalline cellulose, maltodextrin, dibasic potassium phosphate, crospovidone, hypromellose, aspartame, sucrose palmitate, and natural and artificial flavor. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID e72c2bc6-9462-4a2e-8e1d-b97592376cbd. Read the full official label on DailyMed.

Related medicines

Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin